Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Celyad Oncology has announced significant updates regarding its CAR T candidates. The first patient has been dosed with CYAD-211 in the Phase 1 IMMUNICY-1 trial, indicating a key milestone in developing therapies for refractory multiple myeloma. Preclinical results show strong antitumor activity without Graft-versus-Host Disease. Meanwhile, the company has discontinued development of CYAD-01 due to clinical futility observed in the Phase 1 THINK trial. Encouraging initial results for CYAD-02 were reported in the ongoing CYCLE-1 trial.
Celyad Oncology has initiated the Phase 1 IMMUNICY-1 trial, dosing its first patient with CYAD-211, an innovative CAR T therapy targeting BCMA for relapsed/refractory multiple myeloma. The trial will assess safety and efficacy across various dose levels. The company secured €3.4 million in non-dilutive funding from SPW-Recherche to support CYAD-211's development. Preliminary data from the trial is anticipated in the first half of 2021, aiming to address the high unmet need for effective treatments in multiple myeloma.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that CEO Filippo Petti will participate in a fireside chat at the virtual JMP Securities Hematology Summit on December 16, 2020, at 10:00 a.m. ET / 4:00 p.m. CET. A live and archived webcast will be available on the company's website. Celyad Oncology focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, with a pipeline of allogeneic and autologous candidates targeting hematological malignancies and solid tumors. Founded in 2007, the company is based in Mont-Saint-Guibert, Belgium and New York, NY.
Celyad Oncology (CYAD) provided a business update for Q3 2020, emphasizing advancements in its clinical pipeline. Key highlights include a partnership with MSD for a Phase 1b trial of CYAD-101 combined with KEYTRUDA in metastatic colorectal cancer (mCRC) patients. The company is set to initiate the IMMUNICY-1 trial for CYAD-211 by year-end 2020, targeting relapsed/refractory multiple myeloma. As of September 30, 2020, Celyad reported a cash position of €20 million ($23.4 million) and a net cash burn of €6.7 million ($7.8 million), confirming sufficient funds through Q3 2021.
Celyad Oncology (CYAD) announced that three abstracts were accepted for presentation at the 62nd American Society of Hematology Annual Meeting, occurring virtually from December 5-8, 2020. The abstracts will focus on the company’s CAR T candidates: the allogeneic CYAD-211 targeting BCMA, and the autologous CYAD-01 and CYAD-02 based on the NKG2D receptor. The findings will be published in the November issue of the journal Blood. CYAD-211 has received FDA clearance for its IND application, representing progress in CAR T therapy development for multiple myeloma and related cancers.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) has announced its participation in three upcoming healthcare conferences in November 2020. The events are: Bryan, Garnier & Co. Virtual European Healthcare Conference on November 16, Jefferies Virtual London Healthcare Conference on November 17 at 2:55 p.m. ET, and SVB Leerink Oncology 1x1 Day on November 19. The company focuses on developing CAR T therapies for cancer, supported by the Walloon Region funding. Investors can find more details on Celyad's website.
Celyad Oncology (NASDAQ:CYAD) has announced a collaboration with MSD to conduct the Phase 1b KEYNOTE-B79 clinical trial. This trial will investigate the investigational allogeneic CAR T candidate, CYAD-101, in combination with MSD's KEYTRUDA® for treating refractory metastatic colorectal cancer patients. The collaboration aims to leverage the complementary mechanisms of both therapies, potentially addressing unmet needs in microsatellite stable disease. Encouraging results from the alloSHRINK trial provide a positive backdrop for this initiative.
Celyad Oncology, a clinical-stage biotechnology company, announced that CEO Filippo Petti will participate in a fireside chat at the Jefferies Cell Therapy Summit on October 5, 2020, at 11:00 a.m. EDT. The event will be available for investors to listen to via a live webcast on the company's website, with an archived replay accessible for 30 days. Celyad focuses on developing CAR T cell therapies for cancer, including allogeneic and autologous candidates for treating hematological malignancies and solid tumors. The company, founded in 2007, is based in Belgium and New York.
Celyad Oncology (CYAD), a clinical-stage biotechnology company, will host a Research & Development webinar on September 29 at 11:00 a.m. EDT. The webinar will provide insights on its CAR T candidates, CYAD-101 for metastatic colorectal cancer and CYAD-211 for relapsed/refractory multiple myeloma. Dr. Richard Kim will discuss immuno-oncology treatments. Celyad's management will share updates on its pipeline and future directions. Interested participants can register for the live webcast through the company's website, where a replay will also be available post-event.
Celyad Oncology has announced an Open Market Sale Agreement with Jefferies LLC to sell up to $25 million of new American Depositary Shares (ADSs) through an at-the-market offering. The ADSs are priced at $9.91 each, representing a potential issuance of up to 2,777,777 shares. Proceeds from this offering will primarily support the company's CAR T cell therapy research and development initiatives. The offering is registered under a shelf registration statement effective as of September 4, 2020, with additional details available from Jefferies.